
    
      -  Single-center, open label study of pioglitazone in clinically stable patients with mild
           to moderate CF lung disease

        -  Induced sputum will be obtained from each subject at enrollment (Baseline) and again
           following 28 days of pioglitazone treatment (End of Treatment)

        -  Changes in markers of inflammation in the sputum samples will be assessed

        -  Safety measures, including complete blood count (CBC), serum chemistry, Erythrocyte
           sedimentation rate (ESR), C-Reactive Protein (CRP), urinalysis and spirometry, will also
           be assessed
    
  